Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 5;7(1):e1749.
doi: 10.1002/hsr2.1749. eCollection 2024 Jan.

A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK

Stefan Bielack  1 , Christopher P Fox  2 , Khê Hoang-Xuan  3 , Ariadna Giró-Perafita  4 , Carmelo Rizzari  5   6
Affiliations

A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK

Stefan Bielack et al. Health Sci Rep. .

Abstract

Introduction: High-dose methotrexate (HDMTX) is administered for the treatment of some malignancies. Serious complications after the administration of HDMTX are rare, but occasionally MTX may precipitate in the renal tubes causing a delayed elimination leading to renal, multiorgan toxicities and to life-threatening complications. This study aims to estimate the incidence and clinical management of delayed MTX elimination in France, Germany, Italy, and the UK.

Methods: Twelve haemato-oncology and pediatric oncology clinical experts from leading European hospitals participated in the study. A two-round Delphi methodology was used to gather data on different variables relevant to evaluate the HDMTX induced-toxicity impact. For quantitative data, median and interquartile ranges were calculated. Data on prevalence was calculated considering the number of patients in each hospital and the population they cover, and then, extrapolated to the country population.

Results: The total number of patients treated annually with HDMTX in France, Germany, Italy, and the UK is estimated in 7155. Of these, 16% are estimated to develop delayed MTX elimination and around 9% may develop HDMTX-induced acute kidney injury (AKI). Leucovorin, hyperhydration and urine alkalinization are applied to prevent MTX toxicity and precipitation whilst glucarpidase, hemofiltration and hemodialysis are being used for persisting toxic MTX serum levels. Grade 3 systemic toxicities are common in these patients, hematologic and gastrointestinal being the most common ones.

Conclusions: This report provides expert clinical practice experience and opinion of the incidence and management of HDMTX-delayed elimination in France, Germany, Italy and the UK, thereby contributing to the evidence available on this relevant medical condition which can be life-threatening.

Keywords: MTX toxicity clinical management; acute kidney injury (AKI); epidemiology; high‐dose methotrexate (HDMTX); methotrexate delayed elimination.

PubMed Disclaimer

Conflict of interest statement

SB, CPF and KH‐X received consulting fees from BTG. AG‐P is employee of Omakase Consulting S.L. Omakase Consulting S.L. received funding from SERB. CR has received fees from SERB Pharmaceuticals for consultation activities and participation in Advisory Boards.

Similar articles

See all similar articles

References

    1. Vitolo U, Seymour JF, Martelli M, et al. Extranodal diffuse large B‐cell lymphoma (DLBCL) and primary mediastinal B‐cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2016;27:v91‐v102. - PubMed
    1. Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B‐cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2015;26:v116‐v125. - PubMed
    1. Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2016;27:v69‐v82. - PubMed
    1. Casali PG, Bielack S, Abecassis N, et al. Bone sarcomas: ESMO‐PaedCan‐EURACAN clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2018;29:iv79‐iv95. - PubMed
    1. Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978;41:36‐51. - PubMed

LinkOut - more resources